Institutional Ownership
C4 Therapeutics Inc
CUSIP 12529R107COM STKCCCCQ1 2026
13D / 13G Filings
58
Schedule 13D/13G on record
Beneficial Filers
25
Distinct reporting persons
Largest Stake
14.5%
Max % of class reported
Institutional Holders
119
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
58 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Orbimed Advisors LLC | 13G/A | 1.0% | 521.37B | SEC |
| 2 | Feb 17, 2026 | Lynx1 Capital Management LP | 13G/A | 7.3% | 7.10M | SEC |
| 3 | Feb 12, 2026 | Soleus Private Equity Fund III, L.P. | 13G/A | 10.0% | 10.36M | SEC |
| 4 | Feb 11, 2026 | Morgan Stanley | 13G/A | 9.3% | 8.97M | SEC |
| 5 | Nov 14, 2025 | Orbimed Advisors LLC | 13G/A | 5.0% | 16.67T | SEC |
| 6 | Nov 13, 2025 | Wasatch Advisors LP | 13G/A | 6.8% | 4.85M | SEC |
| 7 | Oct 24, 2025 | Ra Capital Management, L.P. | 13G | 9.9% | 9.44M | SEC |
| 8 | Oct 24, 2025 | Bain Capital Life Sciences Fund II, L.P. | 13G | 6.3% | 6.06M | SEC |
| 9 | Oct 20, 2025 | Point72 Asset Management, L.P. | 13G | 9.9% | 22.65M | SEC |
| 10 | Aug 7, 2025 | Morgan Stanley | 13G/A | 6.7% | 4.75M | SEC |
48 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for C4 Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Morgan Stanley | 9.07M | $23.86M |
| 2 | Ra Capital Management, L.P. | 8.00M | $21.04M |
| 3 | Bain Capital Life Sciences Investors, LLC | 7.17M | $18.86M |
| 4 | Lynx1 Capital Management LP | 7.00M | $18.41M |
| 5 | Soleus Capital Management, L.P. | 3.80M | $10.00M |
| 6 | Two Sigma Investments, LP | 3.04M | $7.98M |
| 7 | Wasatch Advisors LP | 2.96M | $7.79M |
| 8 | Jpmorgan Chase & Co | 3.22M | $7.57M |
| 9 | Citadel Advisors LLC | 2.51M | $6.60M |
| 10 | Renaissance Technologies LLC | 2.46M | $6.47M |